MX2019009554A - Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. - Google Patents

Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral.

Info

Publication number
MX2019009554A
MX2019009554A MX2019009554A MX2019009554A MX2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A
Authority
MX
Mexico
Prior art keywords
necrotic enteritis
egg product
clostridium perfringens
poultry
treatment
Prior art date
Application number
MX2019009554A
Other languages
English (en)
Inventor
S Lillehoj Hyun
W Porta Earnest
V Walker Samuel
A Confer Leslie
Deepthi Gadde Ujvala
Gay Cyril
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of MX2019009554A publication Critical patent/MX2019009554A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En un aspecto, la presente invención se dirige a un método para prevenir o tratar la enteritis necrótica administrando un producto de huevo hiperinmunizado obtenido de un animal productor de huevo a un ave. El producto de huevo hiperinmunizado puede contener un anticuerpo específico para un antígeno seleccionado del grupo que consiste de toxina a de Clostridium perfringens, factor de elongación Tu (EF-Tu) de Clostridium perfringens, toxina tipo B de enteritis necrótica (NetB) de Clostridium perfringens, piruvato:oxidorreductasa de Ferredoxina (PFO) de Clostridium perfringens y factor de elongación 1-alfa de Eimeria tenella.
MX2019009554A 2017-02-13 2018-02-13 Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. MX2019009554A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458180P 2017-02-13 2017-02-13
US201762568932P 2017-10-06 2017-10-06
PCT/US2018/018015 WO2018148734A1 (en) 2017-02-13 2018-02-13 Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Publications (1)

Publication Number Publication Date
MX2019009554A true MX2019009554A (es) 2020-01-30

Family

ID=63106738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009554A MX2019009554A (es) 2017-02-13 2018-02-13 Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral.

Country Status (5)

Country Link
US (2) US10450364B2 (es)
BR (1) BR112019016642A2 (es)
CA (1) CA3053150A1 (es)
MX (1) MX2019009554A (es)
WO (1) WO2018148734A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10450364B2 (en) 2017-02-13 2019-10-22 Arkion Life Sciences, Llc Hyperimmunized egg product for treatment of necrotic enteritis in poultry
CN109187964A (zh) * 2018-09-06 2019-01-11 湖北省农业科学院畜牧兽医研究所 一种利用一枚种蛋对禽白血病和鸡沙门氏菌病同时净化检测的方法及其应用
EP3919073B1 (en) * 2020-06-05 2024-05-15 Schweitzer Biotech Company Ltd. Composition for preventing infestation and infection of sea lice on salmon
CN112841133B (zh) * 2021-02-01 2022-04-05 四川农业大学 一种蛋鸡小肠肠炎模型的构建方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
DE69737191T2 (de) 1996-03-26 2007-11-08 Arkion Life Sciences Llc., Wilmington Entzündungshemmende Zusammensetzung aus Ei, Verfahren zur Isolierung und Verwendung
US5772999A (en) 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals
US6803035B2 (en) 1998-05-08 2004-10-12 Arkion Life Sciences Anti-diarrheal and method for using the same
AU2372400A (en) 1999-01-19 2000-08-07 Dcv, Inc. Egg anti-inflammatory composition and method of treating and preventing inflammation
CN1376163A (zh) 1999-07-23 2002-10-23 Dcv公司 高度纯化的细胞因子激活因子和使用方法
US6706267B1 (en) 1999-09-14 2004-03-16 Arkion Life Sciences Llc Glucosamine and egg for reducing inflammation
KR20040105710A (ko) 2002-02-11 2004-12-16 아르키온 라이프 사이언씨즈 엘엘씨 정제된 사이토킨 억제인자
JP3995541B2 (ja) * 2002-06-28 2007-10-24 株式会社ゲン・コーポレーション 抗鶏コクシジウム症組成物
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
US10450364B2 (en) 2017-02-13 2019-10-22 Arkion Life Sciences, Llc Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Also Published As

Publication number Publication date
BR112019016642A2 (pt) 2020-03-31
US20200002404A1 (en) 2020-01-02
CA3053150A1 (en) 2018-08-16
US11230590B2 (en) 2022-01-25
US20180230199A1 (en) 2018-08-16
WO2018148734A1 (en) 2018-08-16
US10450364B2 (en) 2019-10-22

Similar Documents

Publication Publication Date Title
MX2019009554A (es) Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral.
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
AR121361A1 (es) Vacuna
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
BR112021021649A2 (pt) Composições farmacêuticas injetáveis e usos das mesmas
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112019011350A2 (pt) terapia de combinação
BR112015009306A2 (pt) Anticorpos anti-campylobacter jejuni e usos dos mesmos
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
BR112021004464A8 (pt) composição de ração animal e uso da mesma
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
BR112019005217A2 (pt) terapia combinada
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen